Sortiva

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sortiva

Sortiva is a prescription-only medicine for cardiovascular management, whose identity is established by its active compound, Losartan potassium. It is a synthetic compound formulated for oral administration, primarily as a film-coated tablet, and is utilized for the long-term control of high blood pressure (hypertension).

Property Description
Active ingredient Losartan potassium
Form Film-coated tablets
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Control of high blood pressure (hypertension)
Origin Synthetic (non-peptide molecule)

What Type of Medicine is Sortiva? (Identity and Classification)

Sortiva belongs to the specific pharmacological class of Angiotensin II Receptor Blockers (ARBs), formally recognized as Angiotensin-II Receptor Antagonists. This classification places it within the established group of Anti-Hypertensive Drugs used to reduce systemic vascular pressure. The Sortiva brand, containing Losartan potassium, is clinically recognized for its targeted action on the renin-angiotensin system, offering a reliable approach for patients who may require an alternative to older classes of antihypertensives.

Composition and Form: What is Losartan Potassium? (Composition and Form)

The active ingredient in this medication is Losartan potassium, which is consistently prepared for oral administration as film-coated tablets, incorporating an inert pharmaceutical excipient base necessary for tablet integrity. Sortiva is predominantly a single-agent product; however, a widely used combination product, known as Sortiva H, exists. Sortiva H integrates the diuretic Hydrochlorothiazide alongside Losartan potassium, a common strategy to enhance the overall anti-hypertensive effect in complex cases.

Why Is Sortiva Used? (General Purpose)

The fundamental purpose of Sortiva is to promote the control and maintenance of blood pressure in individuals with high blood pressure (hypertension). As an Angiotensin-II Receptor Antagonist, the drug’s primary physiological action is to selectively block the receptor that signals blood vessels to tighten (vasoconstriction). This action allows the blood vessels to relax, efficiently lowering blood pressure and thereby reducing the workload on the heart and circulatory system.

What side effects are possible with Sortiva?

Possible Side Effects and Safety Information

The official safety profile for Sortiva (Losartan potassium) is defined by regulatory agencies through classifications of documented adverse reactions and specific safety constraints. The information presented is derived exclusively from authoritative government sources and reflects the medicine’s risk profile.


Adverse Reaction Frequency and System Involvement

Side effects are categorized by the frequency observed in clinical trials and surveillance. Common reactions (occurring in 1% to 10% of patients) generally include dizziness, headache, upper respiratory infection, nasal congestion, back pain, fatigue, and specific gastrointestinal effects such as diarrhea. Uncommon reactions may include somnolence, vertigo, palpitations, edema, and certain skin reactions like rash or pruritus. Reactions classified as Rare include angioedema (swelling of the face, lips, tongue, and/or throat), hepatitis, and vasculitis. Adverse reactions are grouped by the physiological system affected, such as Nervous System Disorders, Gastrointestinal Disorders, and Musculoskeletal and Connective Tissue Disorders.


Serious Safety Considerations

Serious adverse reactions documented in official labeling include Fetal Toxicity, which involves the risk of injury and death to a developing fetus when the medication is used during the second and third trimesters of pregnancy; therefore, it is contraindicated in these later stages. Other serious risks noted include severe hypotension and hyperkalemia (elevated serum potassium levels).


Population-Specific Constraints

The regulatory profile specifies that the medication is contraindicated for concomitant use with aliskiren in patients with diabetes mellitus. Furthermore, patients with pre-existing impaired renal function, bilateral renal artery stenosis, or severe heart failure are noted to be at an increased risk of acute renal function deterioration.

Overdose and Emergency Response

Overdose and When to Seek Help

Sortiva carries a risk of life-threatening overdose that requires immediate emergency action. This risk is primarily associated with respiratory depression and severe central nervous system (CNS) effects. The possibility of overdose is higher with increased dosages and due to the larger amount of medicine contained in extended-release formulations.


Core Overdose Presentations and Emergency Action

Classification Manifestation/Required Action
Documented Overdose Presentations Slowed, shallow, or difficult breathing; severe sleepiness; or not being able to respond or wake up (unconsciousness).
Physiological Systems Affected Respiratory System, Central Nervous System.
Severity Classification Life-threatening (due to potential respiratory failure).

When Immediate Medical Help is Required

Seek emergency medical help or call 911 immediately if you or someone else experiences any symptoms of severe breathing difficulty, extreme drowsiness, or inability to be awakened. These are signs of a critical, life-threatening emergency.

Procedural Instructions

Emergency care involves administering an opioid overdose reversal agent, such as naloxone, if available, and calling emergency services without delay. Patients are advised to discuss obtaining a reversal agent with their healthcare provider. Overdose risks persist throughout therapy, and patients should never increase the dosage without professional consultation.

Therapeutic Uses of Sortiva

What Sortiva Treats: Main Uses and Benefits

Sortiva (Losartan potassium) is commonly used to provide long-term, supportive relief across key cardiovascular and renal therapeutic domains, generally helping to ease the overall symptomatic burden and supporting functional stability. Its uses are carefully defined by core therapeutic indications.

This medication is primarily relevant for the long-term management of essential hypertension, addressing the chronic symptoms related to systemic imbalance and elevated systemic vascular pressure. It is also used to help mitigate cardiovascular event risk in high-risk patients with co-existing conditions like Left Ventricular Hypertrophy (LVH), and plays a role in the supportive management of symptomatic chronic heart failure. Furthermore, a specific benefit is its use to support patients with Type 2 Diabetes who require protection against the progression of kidney disease.

The general clinical scenario for Sortiva involves chronic management where consistent pressure control is relevant for maintaining patient stability. As a foundational therapy, it supports general well-being during symptomatic phases and contributes to easing the overall strain placed upon the heart and blood vessels.

“The treatment is relevant across therapeutic areas where supportive management of chronic systemic pressure may assist with stability.”


Quick Fact: Relief for Systemic Imbalance Sortiva is commonly used to help manage symptoms related to systemic imbalance by assisting with the sustained control of elevated blood pressure, which generally contributes to easing the overall symptom load.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Sortiva (Losartan potassium) eligibility is strictly defined by regulatory documents, outlining populations permitted to use the medicine, those for whom use is restricted, and those for whom it is formally contraindicated.

Classification Official Eligibility Status
Contraindicated Pregnancy (2nd and 3rd Trimester) must not use Sortiva, due to high risk of fetal harm. Severe Hepatic Impairment and known hypersensitivity to the active substance or excipients are also prohibitions. Patients with diabetes mellitus must not use Sortiva concomitantly with the medicine Aliskiren (dual RAAS blockade is contraindicated).
Restricted Use A lower starting dose (25 mg) is required for patients with mild-to-moderate hepatic impairment or those with volume or salt depletion. Use is allowed but requires caution in patients with bilateral renal artery stenosis.
Age Limits Approved for use in adults and in children 6 years of age and older only for the treatment of hypertension. Use is not recommended in children under 6 years or in pediatric patients with severe renal impairment (GFR < 30 mL/min/1.73 m^2).
Not Recommended The medicine is not recommended for women in the 1st trimester of pregnancy and during breastfeeding.

These constraints ensure that the medicine is administered only to officially defined eligible populations, consistent with safety and efficacy data reviewed by governmental regulatory agencies.

What should I know about interactions with other medicines?

Sortiva Interactions with other medicines and products

Sortiva (Losartan potassium) has officially documented interactions that are based on its pharmacokinetic metabolism and pharmacodynamic effects on blood pressure and electrolytes.

Interaction Classification Interacting Agents Official Statement
Contraindicated Combination Aliskiren Co-administration is formally prohibited in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m^2).
Pharmacokinetic (PK) Modulation Fluconazole (CYP2C9 inhibitor) Documented to decrease the systemic exposure ( AUC) of the active Losartan metabolite by approximately 50%.
Pharmacodynamic Risk Potassium-Sparing Diuretics (e.g., Spironolactone) and Potassium Supplements Concomitant use is generally not recommended due to the documented increased risk of hyperkalemia.
Pharmacodynamic & Renal Risk Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May cause an attenuation of the antihypertensive effect and an increased risk of worsening kidney function.
Clearance Reduction Lithium Use is associated with documented increases in serum lithium concentrations and the risk of toxicity due to reduced renal clearance.

Interaction-Context Constraints

Official labeling documents restrict the use of Sortiva in patients with severe hepatic impairment, a constraint related to the drug's metabolism and the resulting risk of elevated systemic exposure. The prohibition of Aliskiren co-administration is strictly constrained by the patient's underlying condition (Diabetes Mellitus or specific GFR level of renal impairment).

Mechanism of Action

Sortiva's action is defined by its precise interaction with a central hormonal system, resulting in specific physiological effects.


Blocking the Angiotensin II Receptor AT1

This domain covers Sortiva's action as an antagonist that blocks the Angiotensin II type 1 ( AT1) receptor on blood vessel walls and other tissues. By competitively binding to this receptor, Sortiva prevents the vasoconstrictor hormone, Angiotensin II, from signaling, which prevents signaling that causes vasoconstriction.


Modulating the RAAS Cascade

Sortiva modulates the Renin-Angiotensin-Aldosterone System (RAAS), a pathway involved in controlling vascular tension and fluid balance. This mechanism reduces the system's overall activity, resulting in the modulation of systemic vascular resistance and the regulation of sodium and water retention.

Dosage and Administration Information

Official Administration and Dosing Principles

Sortiva (Losartan potassium) is administered exclusively via the oral route, available as a film-coated tablet or, for specific patient needs, an oral suspension. The tablets must be swallowed whole with water and can be taken with or without food. The medication is prescribed for long-term, chronic management and is taken once daily (qDay), with guidance to maintain a consistent time of day to ensure stable drug levels.

Standard Dosing Regimen

The typical adult starting dose for approved indications, such as hypertension, is 50 mg once daily. The dose may be adjusted to a maintenance range up to a maximum recommended dose of 100 mg once daily. Dose adjustments are generally evaluated after 3 to 6 weeks of therapy to allow the full antihypertensive effect to stabilize.

Contextual Adjustments and Missed Doses

A lower initial dose of 25 mg once daily is specifically required for patients with hepatic impairment (liver problems) and for individuals who are clinically volume-depleted. For pediatric patients (6 to 16 years), the official dosing is based on body weight, starting at 0.7 mg/kg once daily, with a total dose not to exceed 50 mg daily. If a scheduled dose is missed, it should be taken as soon as it is remembered, unless it is already near the time for the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

The Research Foundation for Sortiva (Losartan potassium)

This section summarizes the official clinical research for Sortiva (Losartan potassium), detailing the types of studies conducted, the populations they examined, and the primary outcomes measured, as reported in scientific literature.


Evidence for use in Managing High Blood Pressure (Essential Hypertension)

The research relies mainly on Randomized Controlled Trials (RCTs) across both adults and children. Studies monitored changes in blood pressure (systolic and diastolic) over 24-hour periods. Data show patterns related to achieving blood pressure control. Comparative evidence is lacking for direct, long-term cardiovascular outcomes against every other major class of medication.


Evidence Regarding Cardiovascular Event Risk and Left Ventricular Hypertrophy (LVH)

Large-scale, long-term RCTs, typically involving hypertensive adults with LVH, tracked a composite outcome of major cardiovascular events, including stroke and heart attack. These studies compared the research subject to a specific established blood pressure medicine (Atenolol). Research highlights changes measured in the occurrence of stroke in these high-risk patients. Subgroup findings are uncertain regarding whether the observed patterns applied equally to all demographic groups.


Evidence for Kidney Protection in Type 2 Diabetes (Diabetic Nephropathy)

Dedicated, long-term RCTs tracked changes in kidney function for people with Type 2 Diabetes and Diabetic Nephropathy. Researchers monitored proteinuria and the progression of renal disease (e.g., time to dialysis or ESRD). Studies reported patterns related to the progression of specific predefined renal endpoints. Evidence is limited for patients with only very early-stage kidney changes.


Evidence in Specialized Situations and Research Limitations

Sortiva was evaluated in studies involving specific patients with symptomatic chronic heart failure (CHF) who had experienced difficulties with certain established therapies. Data are still emerging for how the medicine performs in a number of less commonly studied patient groups, and the long-term effects on functional status for CHF patients are not fully established. Evidence highlights what is known—and what is still uncertain—especially concerning the consistency of findings over extended periods.

Frequently Asked Questions (FAQ)

Common questions about Sortiva (FAQ)

Q: How long does it usually take to feel the effects of Sortiva?

A: Official information indicates that you may see a substantial lowering of blood pressure within one week of starting Sortiva. However, the maximal therapeutic effect on blood pressure may take a longer time, often between three and six weeks, to fully stabilize.

Q: Does Sortiva cause weight gain or weight loss?

A: Weight changes (either gain or loss) are not listed as a common or uncommon adverse reaction in the official prescribing information for Sortiva. Some patients, however, may report experiencing edema (swelling), which is an uncommon side effect.

Q: Is Sortiva safe for elderly patients to take?

A: Regulatory studies did not show a significant difference in the safety or effectiveness of Sortiva for elderly patients (age 65 and older) compared to younger adults. However, official warnings note that older adults may have an increased risk of hyperkalemia (high potassium levels), which is a factor that healthcare providers consider in monitoring.

Q: Are there special considerations for children or teens taking Sortiva?

A: Sortiva is officially approved for treating high blood pressure in children aged 6 years and older. However, official information states it is not recommended for children under 6 or for children with a specific level of severe renal impairment (significant kidney problems).

Q: Is Sortiva a high-risk medication, or is it generally well-tolerated?

A: The medication is generally considered well-tolerated based on clinical trial data. However, it does carry important, serious risks documented in official warnings. These include the risk of fetal toxicity if used during the last six months of pregnancy, and the potential for severe hypotension (low blood pressure) and hyperkalemia (high potassium levels).

Q: Can Sortiva cause stomach upset or nausea?

A: Yes, regulatory documents list nausea and abdominal pain as common adverse reactions, meaning they occur in 1% to 10% of patients in clinical studies. Diarrhea is also commonly reported.

Q: Are there any common over-the-counter medications that interact with Sortiva?

A: Sortiva is known to interact with certain non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, which are common OTC pain relievers. This combination may be associated with reduced effectiveness at lowering blood pressure and an increased risk of kidney function changes.

Q: Can you take Sortiva with alcohol, or is that risky?

A: Official safety information advises that alcohol can have additive effects with Sortiva in lowering blood pressure. This may cause symptoms like dizziness or fainting. Alcohol may also contribute to a sedative effect (drowsiness).

Q: Does Sortiva interact with common supplements like vitamins or herbal remedies?

A: Regulatory information specifically warns that Sortiva interacts with potassium supplements and salt substitutes containing potassium. Concomitant use with these products is associated with an increased potential for hyperkalemia (dangerously high potassium levels in the blood).

Q: Are there any known long-term effects of taking Sortiva?

A: Sortiva is prescribed for long-term, chronic management of conditions like high blood pressure. Long-term studies conducted for the medication have focused on its ability to reduce the risk of major cardiovascular events (like stroke) and its role in slowing the progression of kidney disease in specific patients.

Q: Why do some people say they feel 'off' when they first start Sortiva?

A: The initial experience of feeling 'off' may be related to common adverse reactions reported in clinical trials. These often include dizziness, headache, and fatigue, all of which are usually mild and may subside as the body adjusts to the medication.

Q: Do you need regular blood tests while you're on Sortiva?

A: Official safety guidelines recommend that healthcare providers consider periodic assessment of serum potassium levels and kidney function (renal function). This is especially true for patients with pre-existing conditions or those taking other interacting medicines.

Q: Is there a generic version of Sortiva available?

A: Yes, the active ingredient in Sortiva, Losartan potassium, has generic versions approved by regulatory agencies like the FDA. These generics contain the same active ingredient and are considered therapeutically equivalent to the brand name product.

Q: Does Sortiva make you feel tired or drowsy during the day?

A: Official safety data lists fatigue as a common adverse reaction. Somnolence (drowsiness or an urge to sleep) is also reported, though less frequently, and may contribute to feeling tired during the day.

Q: Can Sortiva cause problems with driving or operating machinery?

A: Because Sortiva can cause side effects such as dizziness, somnolence, and hypotension (low blood pressure), it is advised to understand how the medication affects an individual before engaging in activities that require full alertness, such as driving or operating machinery.

Q: What is the half-life of Sortiva?

A: The half-life refers to the time it takes for half of the drug to be eliminated from the body. For Sortiva (losartan), the half-life is approximately 2 hours, while the half-life of its highly active metabolite is longer, at about 6 to 9 hours.

Q: Is Sortiva used for short-term or long-term treatment?

A: Sortiva is indicated for long-term, chronic management of its approved conditions, such as high blood pressure and specific kidney problems in type 2 diabetes. It is not typically prescribed for short-term use.

Q: Are there common foods that are known to interact with Sortiva?

A: Yes, regulatory documents indicate that consumption of grapefruit or grapefruit juice should be avoided. This fruit can affect how the body processes Sortiva, and this change in concentration may be associated with reduced therapeutic benefit.

Q: Is it possible for Sortiva to stop working over time?

A: The long-term clinical trials for Sortiva demonstrate that the medication provides a sustained effect on blood pressure and cardiovascular outcomes throughout the study periods. The drug is intended to maintain its therapeutic effects with consistent use.

Q: Why is a slow ramp-up or ramp-down often recommended for Sortiva?

A: Official product information indicates that dose adjustments are typically evaluated after three to six weeks of therapy. This is to allow the full blood pressure lowering effect to stabilize before a maintenance dose is confirmed.

Q: Is Sortiva safe for people with pre-existing heart conditions?

A: The medication is indicated for patients with hypertension and certain heart conditions, such as Left Ventricular Hypertrophy (LVH), to reduce stroke risk. However, official warnings highlight that patients with severe heart failure may be at an increased potential risk of acute kidney function changes.

Q: What are the common benefits people hope to see from taking Sortiva?

A: The officially approved benefits of Sortiva include lowering high blood pressure (hypertension), reducing the risk of stroke in specific high-risk patients, and treating the progression of kidney problems in people with Type 2 diabetes.

Q: Are there different formulations or delivery methods of Sortiva available?

A: Yes, Sortiva (losartan potassium) is available as a film-coated tablet and can also be prepared as an oral suspension. It is also frequently available as a combination product that includes a diuretic (e.g., hydrochlorothiazide) alongside losartan.

Q: Can Sortiva affect mood or cause emotional changes?

A: The official safety profile lists insomnia (difficulty sleeping) as a common adverse reaction. Other psychiatric and nervous system reactions, such as sleep disorder, anxiety, and depression, have also been reported.

How should Sortiva be stored and disposed of?

How to Store and Dispose of Sortiva (Losartan Potassium)

Sortiva tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), to maintain product stability. It is mandatory to keep the medication in the original container, tightly closed, to protect the tablets from moisture and light. The product must be stored out of the sight and reach of children and pets, and must not be frozen.


Disposal Requirements

Do not dispose of unused or expired Sortiva tablets in household waste or by pouring them into wastewater. For proper disposal, patients are instructed to contact their pharmacist or healthcare professional for guidance on local pharmaceutical waste collection programs. This prevents environmental contamination by ensuring the product does not enter sewers or waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sortiva found in:

A-Z Index: